Suppr超能文献

长效β受体激动剂对已接受吸入性糖皮质激素治疗的持续性哮喘患者的治疗作用

Long-acting beta-agonist treatment in patients with persistent asthma already receiving inhaled corticosteroids.

作者信息

Hancox R J, Taylor D R

机构信息

Department of Medical and Surgical Sciences, Dunedin School of Medicine, University of Otago, Dunedin, New Zealand.

出版信息

BioDrugs. 2001;15(1):11-24. doi: 10.2165/00063030-200115010-00002.

Abstract

International guidelines recommend that long-acting beta-agonists should be considered in patients who are symptomatic despite moderate doses of inhaled corticosteroids. When combined with inhaled corticosteroids they improve asthma symptoms and lung function and reduce exacerbations. The evidence suggests that they are well tolerated. However, they are less effective than inhaled corticosteroids as monotherapy and should not be used alone, although the addition of a long-acting beta-agonist may permit a small reduction in the corticosteroid dose. Both salmeterol and formoterol appear equally effective in improving asthma control. Formoterol, however, has a rapid onset of action and is now being promoted for the relief of acute asthma symptoms. Both drugs provide prolonged protection against exercise-induced bronchospasm. However, this effect rapidly diminishes with continuous therapy and if this is the main aim of treatment, intermittent use may be preferable. When compared with alternative treatments, inhaled long-acting beta-agonists are more effective in controlling asthma symptoms than either theophylline or antileukotriene agents. Bambuterol, an oral prodrug of terbutaline, appears to be as effective as the inhaled long-acting beta-agonists and has the advantage of once daily oral administration. However, the inhaled long-acting beta-agonists are less likely to have systemic adverse effects. There are theoretical concerns that regular beta-agonist treatment may lead to tolerance and a failure to respond to emergency asthma treatment. While there is no doubt that tolerance occurs, there is currently little evidence that this is a clinical problem. Insights into pharmacological as well as therapeutic interactions between inhaled corticosteroids and beta-agonists are providing justification for their use in combination. Guidelines for the management of patients with chronic persistent asthma are likely to require modification to reflect these developments.

摘要

国际指南建议,对于尽管使用了中等剂量吸入性糖皮质激素仍有症状的患者,应考虑使用长效β受体激动剂。与吸入性糖皮质激素联合使用时,它们可改善哮喘症状和肺功能,并减少急性发作。有证据表明它们耐受性良好。然而,作为单一疗法,它们的效果不如吸入性糖皮质激素,不应单独使用,尽管添加长效β受体激动剂可能允许糖皮质激素剂量略有减少。沙美特罗和福莫特罗在改善哮喘控制方面似乎同样有效。然而,福莫特罗起效迅速,目前正被推广用于缓解急性哮喘症状。两种药物都能提供针对运动诱发支气管痉挛的长效保护。然而,随着持续治疗,这种效果会迅速减弱,如果这是治疗的主要目标,间歇性使用可能更可取。与其他替代治疗相比,吸入长效β受体激动剂在控制哮喘症状方面比茶碱或抗白三烯药物更有效。班布特罗是特布他林的口服前体药物,似乎与吸入长效β受体激动剂一样有效,且具有每日一次口服给药的优势。然而,吸入长效β受体激动剂产生全身不良反应的可能性较小。理论上担心常规β受体激动剂治疗可能导致耐受性,并对紧急哮喘治疗无反应。虽然毫无疑问会出现耐受性,但目前几乎没有证据表明这是一个临床问题。对吸入性糖皮质激素和β受体激动剂之间药理及治疗相互作用的深入了解为它们联合使用提供了依据。慢性持续性哮喘患者的管理指南可能需要修改以反映这些进展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验